MedTrace Logo

The Role of Spectral Filtering in a Spectrally Adjustable Ocular Photosensitivity Analyzer

NCT04811079 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-04-25

No results posted yet for this study

Summary

This is a 6-visit, single-center, non-dispensing, randomized, single-masked, 5×5 crossover study. Subjects will participate in 6 scheduled over the duration of approximately 10.5 months.

Conditions

  • Photosensitivity

Interventions

OTHER

419 nm Spectacle Filter

TEST

OTHER

437 nm Spectacle Filter

TEST

OTHER

456 nm Spectacle Filter

TEST

OTHER

476 nm Spectacle Filter

TEST

OTHER

373 nm Spectacle Filter

CONTROL

Sponsors & Collaborators

  • Johnson & Johnson Vision Care, Inc.

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson Vision Care, Inc. Clinical Trial · Johnson & Johnson Vision Care, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-14
Primary Completion
2022-05-16
Completion
2022-05-16

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04811079 on ClinicalTrials.gov